Cargando…

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma

The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either circulating IL-5 or its receptor expressed on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagnasco, Diego, Caminati, Marco, Ferrando, Matteo, Aloè, Teresita, Testino, Elisa, Canonica, Giorgio Walter, Passalacqua, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241368/ https://www.ncbi.nlm.nih.gov/pubmed/30519580 http://dx.doi.org/10.1155/2018/5698212

Ejemplares similares

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials
por: Bagnasco, Diego, et al.
Publicado: (2018)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Type 2 immunity in asthma
por: Caminati, Marco, et al.
Publicado: (2018)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Sputum “IL-5, IL-17A, IL-25-high” pattern is associated with uncontrolled asthma and worse lung function
por: Seys, Sven, et al.
Publicado: (2013)

Specific Therapy for T2 Asthma
por: Bagnasco, Diego, et al.
Publicado: (2022)

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017)

Severe asthma: One disease and multiple definitions
por: Bagnasco, Diego, et al.
Publicado: (2021)

Personalized Medicine in Allergy
por: Ferrando, Matteo, et al.
Publicado: (2017)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Comparison of the Asthma Control Questionnaire and patient diaries in uncontrolled asthma
por: Singh, Dave, et al.
Publicado: (2023)

92 Serum CTLA-4 AND IL-10 in Hymenoptera Venom Immunotherapy: Equivalence of Different Induction Regimens
por: Riccio, Anna Maria, et al.
Publicado: (2012)

Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10
por: Riccio, Anna Maria, et al.
Publicado: (2012)

Genetic association of IL2RA, IL17RA, IL23R, and IL31RA single nucleotide polymorphisms with alopecia areata
por: Alghamdi, Mansour A., et al.
Publicado: (2022)

A critical appraisal on AIT in childhood asthma
por: Ferrando, Matteo, et al.
Publicado: (2018)

The WEB-based Asthma Control: an intriguing connection or a dangerous hazard?
por: Lombardi, Carlo, et al.
Publicado: (2015)

Asthma research and practice: a new journey begins
por: Celedon, Juan C., et al.
Publicado: (2015)

Allergen immunotherapy in asthma; what is new?
por: Passalacqua, Giovanni, et al.
Publicado: (2015)

Uncontrolled Asthma: Unmet Needs in the Management of Patients
por: Caminati, Marco, et al.
Publicado: (2021)

Interleukin-5 in the Pathophysiology of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2019)

Editorial: Innate immunity and severe asthma: From microbiome to target therapy
por: Bagnasco, Diego, et al.
Publicado: (2022)

Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β
por: Gao, Peng, et al.
Publicado: (2015)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
por: Bagnasco, Diego, et al.
Publicado: (2023)

Anti-IL5 therapy for asthma and beyond
por: Mukherjee, Manali, et al.
Publicado: (2014)

Association of IL10RA, IL10RB, and IL22RA Polymorphisms/Haplotypes with Susceptibility to and Clinical Manifestations of SLE
por: Grk, Milka, et al.
Publicado: (2023)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
por: Drick, Nora, et al.
Publicado: (2020)

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD
por: Drick, Nora, et al.
Publicado: (2022)

Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

COVID-19, Eosinophils, and Biologicals for Severe Asthma
por: Lombardi, Carlo, et al.
Publicado: (2022)

Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?
por: Lombardi, Carlo, et al.
Publicado: (2017)

Investigation on Probable Association Between IL-13, IL-13RA1, and IL-13RA2 Genes Polymorphism and Pulmonary Tuberculosis
por: Li, Hong-Miao, et al.
Publicado: (2022)

Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study
por: Isidoro-García, María, et al.
Publicado: (2005)

Treating severe asthma: Targeting the IL‐5 pathway
por: Principe, Stefania, et al.
Publicado: (2021)

A Brief History of IL-1 and IL-1 Ra in Rheumatology
por: Dayer, Jean-Michel, et al.
Publicado: (2017)

The role of cytokines in seizures: interleukin (IL)-1β, IL-1Ra, IL-8, and IL-10
por: Youn, Youngah, et al.
Publicado: (2013)

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
por: May, RD, et al.
Publicado: (2012)

IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial
por: Crim, Courtney, et al.
Publicado: (2022)

Combined Analysis of IFN-γ, IL-2, IL-5, IL-10, IL-1RA and MCP-1 in QFT Supernatant Is Useful for Distinguishing Active Tuberculosis from Latent Infection
por: Suzukawa, Maho, et al.
Publicado: (2016)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jq27uqs2qkbi05e7e11p3s24ga